These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 12180645)
1. In search of authentic inhibitors of HIV-1 integration. Debyser Z; Cherepanov P; Van Maele B; De Clercq E; Witvrouw M Antivir Chem Chemother; 2002 Jan; 13(1):1-15. PubMed ID: 12180645 [TBL] [Abstract][Full Text] [Related]
2. HIV-1 integration as a target for antiretroviral therapy: a review. Pluymers W; De Clercq E; Debyser Z Curr Drug Targets Infect Disord; 2001 Aug; 1(2):133-49. PubMed ID: 12455410 [TBL] [Abstract][Full Text] [Related]
3. Novel inhibitors of HIV-1 integration. Witvrouw M; Van Maele B; Vercammen J; Hantson A; Engelborghs Y; De Clercq E; Pannecouque C; Debyser Z Curr Drug Metab; 2004 Aug; 5(4):291-304. PubMed ID: 15320701 [TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of HIV-1 integrase inhibitors--enzyme-ligand interactions. Maurin C; Bailly F; Cotelle P Curr Med Chem; 2003 Sep; 10(18):1795-810. PubMed ID: 12871105 [TBL] [Abstract][Full Text] [Related]
5. HIV type 1 integrase inhibitors: from basic research to clinical implications. Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719 [TBL] [Abstract][Full Text] [Related]
6. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Hazuda DJ; Felock P; Witmer M; Wolfe A; Stillmock K; Grobler JA; Espeseth A; Gabryelski L; Schleif W; Blau C; Miller MD Science; 2000 Jan; 287(5453):646-50. PubMed ID: 10649997 [TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid. Lee DJ; Robinson WE J Virol; 2004 Jun; 78(11):5835-47. PubMed ID: 15140981 [TBL] [Abstract][Full Text] [Related]
8. Combinations of reverse transcriptase, protease, and integrase inhibitors can be synergistic in vitro against drug-sensitive and RT inhibitor-resistant molecular clones of HIV-1. Beale KK; Robinson WE Antiviral Res; 2000 Jun; 46(3):223-32. PubMed ID: 10867160 [TBL] [Abstract][Full Text] [Related]
9. HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial. Johnson AA; Marchand C; Pommier Y Curr Top Med Chem; 2004; 4(10):1059-77. PubMed ID: 15193139 [TBL] [Abstract][Full Text] [Related]
10. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Garvey EP; Johns BA; Gartland MJ; Foster SA; Miller WH; Ferris RG; Hazen RJ; Underwood MR; Boros EE; Thompson JB; Weatherhead JG; Koble CS; Allen SH; Schaller LT; Sherrill RG; Yoshinaga T; Kobayashi M; Wakasa-Morimoto C; Miki S; Nakahara K; Noshi T; Sato A; Fujiwara T Antimicrob Agents Chemother; 2008 Mar; 52(3):901-8. PubMed ID: 18160521 [TBL] [Abstract][Full Text] [Related]
11. Biochemical screening assays to identify HIV-1 integrase inhibitors. Clynhens M; Smets A; Vereycken I; Van Loock M; Clayton R; Meersseman G; Goethals O Methods Mol Biol; 2013; 1030():25-36. PubMed ID: 23821258 [TBL] [Abstract][Full Text] [Related]
12. Peptides as new inhibitors of HIV-1 reverse transcriptase and integrase. de Soultrait VR; Desjobert C; Tarrago-Litvak L Curr Med Chem; 2003 Sep; 10(18):1765-78. PubMed ID: 12871103 [TBL] [Abstract][Full Text] [Related]
13. Recent progress in the development of inhibitors of human immunodeficiency virus (HIV) integrase for the management of HIV infection. Lin SS; Xu F; Liao PH; Yang CC Acta Virol; 2008; 52(4):197-207. PubMed ID: 19143475 [TBL] [Abstract][Full Text] [Related]
14. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Hazuda DJ; Anthony NJ; Gomez RP; Jolly SM; Wai JS; Zhuang L; Fisher TE; Embrey M; Guare JP; Egbertson MS; Vacca JP; Huff JR; Felock PJ; Witmer MV; Stillmock KA; Danovich R; Grobler J; Miller MD; Espeseth AS; Jin L; Chen IW; Lin JH; Kassahun K; Ellis JD; Wong BK; Xu W; Pearson PG; Schleif WA; Cortese R; Emini E; Summa V; Holloway MK; Young SD Proc Natl Acad Sci U S A; 2004 Aug; 101(31):11233-8. PubMed ID: 15277684 [TBL] [Abstract][Full Text] [Related]
16. The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy. Christ F; Debyser Z Virology; 2013 Jan; 435(1):102-9. PubMed ID: 23217620 [TBL] [Abstract][Full Text] [Related]
17. Design and development of integrase inhibitors as anti-HIV agents. Gupta SP; Nagappa AN Curr Med Chem; 2003 Sep; 10(18):1779-94. PubMed ID: 12871104 [TBL] [Abstract][Full Text] [Related]
18. HIV-1 integrase and RNase H activities as therapeutic targets. Andréola ML; De Soultrait VR; Fournier M; Parissi V; Desjobert C; Litvak S Expert Opin Ther Targets; 2002 Aug; 6(4):433-46. PubMed ID: 12223059 [TBL] [Abstract][Full Text] [Related]
19. Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1. Cherepanov P; Esté JA; Rando RF; Ojwang JO; Reekmans G; Steinfeld R; David G; De Clercq E; Debyser Z Mol Pharmacol; 1997 Nov; 52(5):771-80. PubMed ID: 9351967 [TBL] [Abstract][Full Text] [Related]
20. Anti-HIV-1 integrase drugs: how far from the shelf? Pani A; Marongiu ME Curr Pharm Des; 2000 Mar; 6(5):569-84. PubMed ID: 10788597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]